Deals Update (01/2008)
A roundup of recent medtech strategic alliances, mergers & acquisitions and financings.
You may also be interested in...
Drug companies involved in Alzheimer's disease research are a little fed up with FDA. Some, like Wyeth, believe the agency should put Alzheimer's research higher up on its priority list and allow the use of surrogate endpoints for clinical trials. But FDA says that no validated surrogate exists for Alzheimer's, and until it has hard data from products in development, it is loath to recommend one. A recent reorganization of the agency's neurology group may provide an opening to press home those arguments.
The European Medicines Agency's human medicines committee has recommended the suspension of marketing authorizations for around 100 generics after identifying “irregularities” in how bioequivalence studies were conducted by Synchron Research Services.
India's Sun Pharma has expanded the portfolio of its Romanian subsidiary Terapia with the acquisition of the Uractiv urinary tract health brand.